IRLAB A — IRLAB Therapeutics AB Cashflow Statement
0.000.00%
- SEK366.71m
- SEK360.21m
- SEK94.63m
Annual cashflow statement for IRLAB Therapeutics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -91.5 | 52.6 | -113 | -181 | -75.1 |
Non-Cash Items | 2.06 | 41.8 | 4.48 | 7.24 | 0.52 |
Other Non-Cash Items | |||||
Changes in Working Capital | 0.182 | 34.3 | -34 | 8.67 | 9 |
Change in Accounts Receivable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -89.2 | 129 | -143 | -165 | -65.6 |
Capital Expenditures | -0.394 | -0.708 | -2.88 | -0.293 | -0.199 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | -0.5 | 0 | — |
Acquisition of Business | |||||
Sale of Business | |||||
Cash from Investing Activities | -0.394 | -0.708 | -3.38 | -0.293 | -0.199 |
Financing Cash Flow Items | 0.001 | — | — | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 256 | -3.04 | -3.13 | 23.7 | 21.4 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 166 | 125 | -149 | -141 | -44.4 |